Skip to main content

$0.220 (0%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
11 October 2024 at 3:11am
Register to track AYA and receive email alerts.

Artrya Limited, a medical technology company, engages in the development and commercialisation of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. The company offers Salix, a cloud-based software that uses its AI to automate the detection of coronary artery disease from coronary computed tomography angiography scans which identifies and manages patients at risk of a heart attack. Artrya Limited was incorporated in 2018 and is based in West Perth, Australia.

Expand Company Description

Market Cap (10-Oct)

$27,170,592 (0th)

Close (30-Jun)

$0.220

Volume (30-Jun)

0

Shortsold (2-Apr)

11,780 (0.01%) (529th)

52w High

$0.420

52w Low

$0.160

P/E

-

EPS

-0.18
Subject
AYA Ann: Notification of cessation of securities - AYA

AYA Ann: Application for quotation of securities - AYA

AYA Ann: Secondary Trading Notice

AYA Ann: Company Presentation - MST Digital Health Forum

AYA Ann: AYA Conducts Successful Q-Submission Meeting with FDA

AYA Ann: Change of Director's Interest Notice - K Hill

AYA Ann: Artrya Lodges Key Submission in FDA Process

AYA Ann: Becoming a substantial holder

AYA Ann: Quarterly Activity Report and Appendix 4C-March 2023

AYA Ann: Investor Presentation

AYA Ann: Change of Director's Interest Notice - B Ridgeway

AYA Ann: Notification regarding unquoted securities - AYA

AYA Ann: Final Director's Interest Notice - J Barrington

AYA Ann: Proposed issue of securities - AYA

AYA Ann: Board and Management Changes

AYA Ann: Change of Director's Interest Notice - K Hill

AYA Ann: Change of Director's Interest Notice - K Hill

AYA Ann: Initial and Change in Directors' Intrests

AYA Ann: Artrya Strengthens Board with new Director

AYA Ann: Appendix 4D and Half Year Financial Report

AYA Ann: Presentation - Euroz Hartleys Healthcare Forum 2023

AYA Ann: Quarterly Activity Report and Appendix 4C

AYA Ann: Change of Director's Interest Notice - J Barrington

AYA Ann: Change in Substantial Holding - Artrya

AYA Ann: Change in Director's Interest Notice - J Barrington

AYA Ann: Notification regarding unquoted securities - AYA

AYA Ann: Release of shares from voluntary escrow

AYA Ann: Results of Meeting

AYA Ann: Chairman and Managing Director Addresses to AGM

AYA Ann: Notification of cessation of securities - AYA

AYA Ann: Initial Director's Interest Notice

AYA Ann: Notification regarding unquoted securities - AYA

AYA Ann: Artrya - Bell Potter Health Care Conference 2022

AYA Ann: Artrya Gains UK Regulatory Approval

AYA Ann: Application for quotation of securities - AYA

AYA Ann: Artrya Successful in Gaining European Regulatory Approval

AYA Ann: Quarterly Activity Report and Appendix 4C

AYA Ann: Letter to Shareholders - Annual General Meeting

AYA Ann: Proxy Form - Annual General Meeting

AYA Ann: Notice of Annual General Meeting

AYA Ann: Artrya Annual Report 2022

AYA Ann: Appointment of Company Secretary

AYA Ann: Notification regarding unquoted securities - AYA

AYA Ann: Application for quotation of securities - AYA

AYA Ann: Appendix 4G and Corporate Governance Statement

AYA Ann: Appendix 4E and Annual Financial Report 30 June 2022

AYA Ann: Artrya Strengthens Board with US-based Director

AYA Ann: Updated Appendix 4C for Q4 FY22

AYA Ann: Quarterly Activity Report and Appendix 4C for Q4 FY22

AYA Ann: Quarterly Results Conference Call

Register to track AYA and receive email alerts.